Wechselwirkungen · Nucala
Nucala 100 mg solution for injection in pre-filled pen Nucala 100 mg solution for injection in pre-filled syringe Nucala 40 mg solution for injection in pre-filled syringe · Abschnitt 4.5 · PDF-Seite 7
HOS-132563 · Präparat HOS-097252
Cytochrome P450 enzymes, efflux pumps and protein-binding mechanisms are not involved in the clearance of mepolizumab. Increased levels of pro-inflammatory cytokines (e.g. IL-6), via interaction with their cognate receptors on hepatocytes, have been shown to suppress the formation of CYP450 enzymes and drug transporters, however, elevation of systemic pro-inflammatory markers in severe refractory eosinophilic asthma is minimal and there is no evidence of IL-5 receptor alpha expression on hepatocytes. The potential for interactions with mepolizumab is therefore considered low.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-22T16:02:00Z · SHA-256 297766dd530d777167969a87af3c0ff120dce3cd78dcb8c4ddbec012a3bcb033 · Passage 46333a40f68840758c7a73d951a143e0ad3c212ab4e9bd6b7396fd76afa57662 · Zeichen 45–627 im Abschnitt